Metformin

A study led by the Mayo Clinic using funds from Three Lakes Foundation demonstrated that patients with both pulmonary fibrosis and type 2 diabetes treated with metformin

had a significant reduction in mortality and hospitalizations. Data from over 3,500 patients with IPF and type 2 diabetes was analyzed from a nationwide cohort using the

OptumLabs Data Warehouse.

Based on these results and evidence from animal model efficacy studies with metformin, additional funding has been obtained to conduct a clinical trial to validate whether patients with pulmonary fibrosis benefit from treatment with metformin.

The principal investigator for this work was Andrew Limper, MD, Professor of Medicine and Professor of Biochemistry and Molecular Biology at the Mayo Clinic.

“Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis” was published in Respiratory Research. 

Read More